The companies are aiming to develop Idylla-based CDx biomarker tests for a compound Amgen is developing to treat solid tumors.
The companies are seeking to register Biocartis' Idylla RAS biomarker tests with the FDA as companion diagnostics for Amgen's Vectibix.
Adaptive Biotechnologies will measure minimal residual disease in multiple myeloma patients as part of an Amgen-sponsored clinical trial.
The one-year partnership will focus on identifying patients with abnormal pain conditions and validating the genetic findings as potential targets for drugs.
The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.
In Nature this week: paternal age associated with de novo mutations in children, and more.
An analysis of more than 1,500 Icelandic families suggests new mutations in children born to older Moms are distinct and tend to cluster in some parts of the genome.
Illumina and Amgen co-developed the test, which will determine whether metastatic colorectal cancer patients will benefit from Vectibix.
Researchers identified truncating, psychosis-related mutations in RBM12 in a family affected by schizophrenia or other psychosis disorders.
Using extensive genetic data from an Icelandic population, researchers identified two rare variants associated with osteoarthritis and related hip replacements.
A letter criticizing actions by the US government and research institutions toward Chinese and Chinese-American scientists has garnered more than a hundred signatories.
NPR reports that researchers in New York are investigating whether it is possible to edit the genomes of human sperm.
In an opinion piece at the Nation, Sarah Lawrence College's Laura Hercher argues that everyone should be able to access prenatal genetic testing.
In Nature this week: ancient DNA uncovers presence of Mediterranean migrants at a Himalayan lake, and more.